Pharma&Biotech Audited

Pharma&Biotech facts

Lonza’s Pharma&Biotech vision is to enable our customers to meet some of the greatest challenges in patient treatment. The Pharma&Biotech market-focused segment comprises the following businesses:


As of 1 January 2018, the Pharma&Biotech segment is operating with a Chemical Division and a Biologics Division, as well as the existing Bioscience Solutions Business Unit and a new Capsule Delivery Solutions Business Unit. The latter business unit will cover the capsules business for pharma markets. Capsugel’s dosage forms and development services have been integrated in the newly formed Dosage Forms and Delivery Systems (DFDS) Business Unit within the Chemical Division.


Pharma&Biotech Overview 2017


Pharma&Biotech saw another record year in 2017 with commercial excellence, robust operational execution and business-model innovation as key performance drivers. The continued outstanding performance was supported by high demand across all businesses with strong development in Commercial Mammalian and in Chemical Manufacturing, as well as ongoing high demand for Clinical Development services.

The segment (Lonza standalone) delivered remarkable sales growth of 18.9% (19.4% in constant exchange rates), reaching CHF 2.1 billion, which led to an excellent CORE EBIT of CHF 530 million and an extremely high 31.8% CORE EBIT growth year over year. Pharma&Biotech expects to continue the momentum in 2018 by benefiting from continued strong demand in the global pharma market and by covering the entire value chain with the broadest set of technology platforms in the contract development and manufacturing industry – mammalian, microbial, chemical, bioconjugates, cell and gene therapy.

Pharma&Biotech Financial Summary 1,2 

million CHF 2017 Change in % 2016
Sales 2,124 18.9 1,786
CORE EBIT3 530 31.8 402
CORE EBIT margin in % 25.0   22.5
CORE EBITDA3 659 25.3 526
CORE EBITDA margin in % 31.0   29.5

CORE EBITDA (in million CHF) and CORE EBITDA Margin Progression